Posted by MarketBeat News on Nov 21st, 2024
StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research report issued on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Separately,...
More of this article »